Search

Primer on Cerebrovascular Diseases, Second Edition, is a handy reference source for scientists, students, and physicians needing reliable, up-to-date information on basic mechanisms, physiology, pathophysiology, and medical issues related to brain vasculature. The book consists of short, specific chapters written by international experts on cerebral vasculature, presenting the information in a comprehensive and easily accessible manner. Numerous changes have occurred in the field since the publication of the first edition in 1997, particularly our understanding of the genetic aspects of cerebrovascular disease. This updated edition reflects the advances made over the last two decades, not only demonstrating the promise for therapy, but also for a molecular understanding of cerebrovascular diseases. The new edition includes new and expanded topics, including carotid stenting, Iatrogenic causes of stroke, axonal transport and injury, RNAIs, proteomics, and more. 2018 BMA Medical Book Awards Highly Commended in Neurology. - Provides concise chapters on topics in cerebral blood flow and metabolism, pathogenesis of cerebrovascular disorders, diagnostic testing, and management in a comprehensive and accessible format - Written by international leading authorities on cerebral vasculature - Provides up-to-date information on practical applications of basic research and the main clinical issues facing the community, such as axonal transport and proteomics

While there are a number of books on the market that deal with neuronal mechanisms and targets, the proposed book will be the only one to cover the vascular aspects of CNS trauma. The contributing authors will present basic mechanisms, explain cutting-edge experimental models and techniques, and provide several clinical chapters that provide treating physicians with some insight on the cases that they see in the ICU. The table of contents is diverse and comprehensive with chapters on molecular mechanisms, physiology, pharmacology, stem cells, genomics and proteomics, in vivo MRI and PET, as well as the clinical management of vascular parameters.​

White matter injury can result from both ischemic and hemorrhagic stroke as well as a host of other CNS diseases and conditions such as neonatal injuries, neurodegenerative disorders including Alzheimer's disease, traumatic brain injuries, carbon monoxide poisoning, and drug or alcohol overdoses. The extent of white matter injury is extremely important to patient outcomes. Several recent technological developments including advanced neuroimaging and the breeding of new rodent models of white matter injury have provided growing insight into initial damage and repair after a stroke or other damaging event. The proposed book will be the first to provide a systematic expert summary of normal white matter morphology as well as white matter injury following stroke and other CNS injuries.

Cerebral amyloid angiopathy (CAA) is a distinctive abnormality of small cerebral blood vessels, one that has intrigued neuroscientists for decades. The time seems right for a book which examines the phenomenon of CAA using a multifaceted approach: What does it produce clinically? How might CAA be imaged? What are the crucial biochemical/cellular events within cerebral vessel walls that lead to CAA? How can in vitro or transgenic experimental systems be used to understand the etiology of, or even potential treatments for, CAA? The editors have assembled key figures in the field of CAA research to examine these (and other) questions in a series of focused chapters that address specific issues of importance in understanding CAA and its clinical manifestations. Comprehending the biology and pathogenesis of this fascinating vascular lesion may even provide clues to less common forms of cerebral microvascular disease that have been recognized for decades (hypertensive microangiopathy) or more recently (CADASIL).

A comprehensive, state-of-the-art contribution to a field that is rapidly developing, The Behavioral Consequences of Stroke provides a broad overview of the cognitive and neurobehavioral effects of stroke. As attention to paralysis and the more obvious physical disabilities stroke patients incur expands, greater attention is being paid today to the cognitive and neurobehavioral complications that impact stroke morbidity and even functional neurological recovery in patients. Written by an international panel of experts and edited by a neurosurgeon and by a cognitive neuroscientist, this unique title addresses the full range of issues relevant to the field, including epidemiology, general treatment, sensorimotor control after stroke, post-stroke aphasia, memory loss after stroke, post-stroke depression, the role of imaging after a stroke, and an update on some stroke clinical trials, to name just some of the areas covered. Illuminative and an influential addition to the literature, The Behavioral Consequences of Stroke will serve as an invaluable resource for neurologsits, neurosurgeons, physiatrists and other physicians, as well as physical, speech and occupational therapists, nurses, psychologists, and other professionals.

Stroke is a major cause of death and disability in the U.S. and worldwide. A variety of pathophysiologic episodes or cellular medications occur following a stroke, and knowledge of these aftermath events can lead to potential therapeutic strategies that may reverse or attenuate stroke injury. Cellular events that occur following stroke include the excessive releases of excitatory amino acids, alterations in the genomic responses, mitochondrial injury producing reactive oxygen and nitrogen species (ROS), and secondary injury, often in the setting of reperfusion.

This volume sets a basis for effective translational research. Authored by experts in the field of translational stroke research, each chapter specifically addresses one or more components of preclinical stroke research. The emphasis is placed on target identification and drug development using state-of-the-art in vitro and in vivo assays, in combination with in vitro toxicology assays, AMDE and clinical design.